COMP <GO>
GRCE vs DWTX // EV/EBITDA & P/E VALUATION
Grace Therapeutics Inc. (NASDAQ) VS. Dogwood Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: GRCE 2
— DWTX 1
■ METRIC PARITY
LAST: $1.94 (-3.48%) • MKT CAP: $40.8M
valuation
—
LAST: $1.23 (-0.81%) • MKT CAP: $41.8M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GRCE VS. DWTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GRCE | DWTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -18.90% | -32.30% | +13.40 | GRCE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -21.73% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.2 | 44.1 | +2.10 | GRCE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.8M | $41.8M | -$1.0M | DWTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GRCE REV | DWTX REV | GRCE GROSS % | DWTX GROSS % | GRCE FCF | DWTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$8.9M | -$15.6M |
| FY 2024 | $0 | $0 | — | — | -$14.9M | -$8.8M |
| FY 2023 | $0 | $0 | — | — | -$12.3M | -$4.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GRCE // BETA —
DWTX // BETA —